Chemotherapy-Induced Anemia in Adults Incidence and Treatment

Öz

Chemotherapy-induced anemia is the predominant adverse event observed in individuals undergoing cancer treatment, resulting in a reduction in red blood cells and hemoglobin levels. This condition manifests through indicators such as diminished quality of life and fatigue. Effective approaches for managing recurrent chemotherapy-induced anemia encompass the use of erythropoietin-stimulating agents, blood transfusions, and intravenous iron supplementation. Each of these interventions presents distinct pros and cons, with selecting a particular treatment modality contingent upon the severity of anemia and the duration of malignancy. A comprehensive review of scholarly literature reveals a high prevalence of anemia among cancer patients receiving chemotherapy. Ongoing research endeavors are focused on developing pharmacological agents for cancer treatment that are devoid of adverse effects, particularly concerning anemia, a common complication associated with this therapeutic approach.

Anahtar Kelimeler

• Anemia, Cancer,
• Chemotherapy
• erythropoietin

Kaynakça

1. 1Radziwon P, Krzakowski M, Kalinka E, Zaucha R, Wysocki P, Kowalski D, Gryglewicz J, Wojtukiewicz MZ. Anemia in cancer patients—Expert Group recommendations. Revision 2020. Hematology in Clinical Practice. 2020;11(1):1-11.
2. Van Belle SJ-P, Cocquyt V. Impact of haemoglobin levels on the outcome of cancers treated with chemotherapy. Critical reviews in oncology/hematology. 2003;47(1):1-11.
3. Gilreath JA, Stenehjem DD, Rodgers GM. Diagnosis and treatment of cancer‐related anemia. American journal of hematology. 2014;89(2):203-12.
4. Langer CJ, Choy H, Glaspy JA, Colowick A. Standards of care for anemia management in oncology: focus on lung carcinoma. Cancer: Interdisciplinary International Journal of the American Cancer Society. 2002;95(3):613-23.
5. Kano Y, Kajiwara K, Kozai YJTAJotMS. Cancer-related Microangiopathic Hemolytic Anemia2023;365(2):e15-e6.
6. Xu J, Wu K, Li X, Teo CS, Li G, Pan Y, Hou LJJoTCMS. Effectiveness and safety of seven oral Chinese patent medicines as adjuvant therapy for cancer-related anemia: A systematic review and network meta-analysis of randomized controlled trials2023.
7. Gilreath JA, Rodgers GMJB, The Journal of the American Society of Hematology. How I treat cancer-associated anemia2020;136(7):801-13.
8. Hess G, Nordyke RJ, Hill J, Hulnick S. Effect of reimbursement changes on erythropoiesis‐stimulating agent utilization and transfusions. American journal of hematology. 2010;85(11):838-43.

9. Steensma DP. Is anemia of cancer different from chemotherapy-induced anemia? Journal of Clinical Oncology. 2008;26(7):1022-4.
10. Adamson JW. The anemia of inflammation/malignancy: mechanisms and management. ASH Education Program Book. 2008;2008(1):159-65.
11. Foundation NK. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. American journal of kidney diseases: the official journal of the National Kidney Foundation. 2006;47(5 Suppl 3):S11-S145.
12. Анемії К. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney international. 2012;2:279.
13. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. Journal of the National Cancer Institute. 1999;91(19):1616-34.
14. Jefferies S, Rajan B, Ashley S, Traish D, Brada M. Haematological toxicity of cranio-spinal irradiation. Radiotherapy and oncology. 1998;48(1):23-7.
15. Dessypris E. The biology of pure red cell aplasia. Semin Hematol. 1991;28:275-84.
16. Wang SA, Yue G, Hutchinson L, Landry ML, Hasserjian RP, Hao S, Galili N, Raza A, Woda BA. Myelodysplastic syndrome with pure red cell aplasia shows characteristic clinicopathological features and clonal T‐cell expansion. British journal of haematology. 2007;138(2):271-5.
17. Cheng Z, Yan M, Lu Y, Pan X-TJH. Expression of serum BMP6 and hepcidin in cancer-related anemia2020;25(1):134-8.
18. Muthanna FM, Samad A, Ibrahim HK, Al-Awkally N-AM, Sabir SJIJoHS. Cancer related anaemia (CRA): An overview of approach and treatment2022(II):2552-8.
19. Gordon M, Kearney L, Hibbin J. Effects of human marrow stromal cells on proliferation by human granulocytic (GM‐CFC), erythroid (BFU‐E) and mixed (Mix‐CFC) colony‐forming cells. British Journal of Haematology. 1983;53(2):317-25.
20. Kobune M, Kawano Y, Kato J, Ito Y, Chiba H, Nakamura K, Fujimi A, Matsunaga T, Hamada H, Niitsu Y. Expansion of CD34+ cells on telomerized human stromal cells without losing erythroid-differentiation potential in a serum-free condition. International journal of hematology. 2005;81:18-25.
21. Werner TL, Agarwal N, Carney HM, Rodgers GM. Management of cancer‐associated thrombotic microangiopathy: What is the right approach? American journal of hematology. 2007;82(4):295-8.
22. Madeddu C, Neri M, Sanna E, Oppi S, Macciò AJJoEP. Experimental drugs for chemotherapy-and cancer-related anemia2021:593-611.
23. Abiri B, Vafa MJN, cancer. Iron deficiency and anemia in cancer patients: the role of iron treatment in anemic cancer patients2020;72(5):864-72.
24. Abdel-Razeq H, Hashem HJCrioh. Recent update in the pathogenesis and treatment of chemotherapy and cancer induced anemia2020;145:102837.
25. Chant C, Wilson G, Friedrich JO. Anemia, transfusion, and phlebotomy practices in critically ill patients with prolonged ICU length of stay: a cohort study. Critical care. 2006;10:1-9.
26. Amato A, Pescatori M. Perioperative blood transfusions and recurrence of colorectal cancer. Cochrane database of systematic reviews. 2006(1).
27. Kirshner J, Hatch M, Hennessy DD, Fridman M, Tannous RE. Anemia in stage II and III breast cancer patients treated with adjuvant doxorubicin and cyclophosphamide chemotherapy. The oncologist. 2004;9(1):25-32.
28. Rodgers GM, Becker PS, Blinder M, Cella D, Chanan-Khan A, Cleeland C, Coccia PF, Djulbegovic B, Gilreath JA, Kraut EH. Cancer-and chemotherapy-induced anemia. Journal of the National Comprehensive Cancer Network. 2012;10(5):628-53.
29. Grotto H. Anaemia of cancer: an overview of mechanisms involved in its pathogenesis. Medical oncology. 2008;25:12-21.
30. Natalucci V, Virgili E, Calcagnoli F, Valli G, Agostini D, Zeppa SD, Barbieri E, Emili RJN. Cancer related anemia: an integrated multitarget approach and lifestyle interventions2021;13(2):482.
31. Aapro MS. Anemia Management with Erythropoiesis-Stimulating Agents: A Risk–Benefit Update. Oxford University Press; 2008. p. 1-3.
32. Al-Refaie WB, Parsons HM, Markin A, Abrams J, Habermann EB. Blood transfusion and cancer surgery outcomes: a continued reason for concern. Surgery. 2012;152(3):344-54.
33. Arezes J, Jung G, Gabayan V, Valore E, Ruchala P, Gulig PA, Ganz T, Nemeth E, Bulut Y. Hepcidin-induced hypoferremia is a critical host defense mechanism against the siderophilic bacterium Vibrio vulnificus. Cell host & microbe. 2015;17(1):47-57.
34. Abdel-Razeq HN. Cancer-related anemia. Saudi medical journal. 2004;25(1):15-20.
35. Ramli NA, Iberahim S, Ismail AAC, Hussin HJCJoIM. Incidence of anemia and red blood cell (RBC) transfusion requirement in breast cancer2023;14(2):237.
36. Abdel-Razeq H, Hashem H. Recent update in the pathogenesis and treatment of chemotherapy and cancer induced anemia. Critical reviews in oncology/hematology. 2020;145:102837.
37. Cosse J-P, Michiels C. Tumour hypoxia affects the responsiveness of cancer cells to chemotherapy and promotes cancer progression. Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents). 2008;8(7):790-7.
38. Prince M, Wimo A, Guerchet M, Ali G-C, Wu Y-T, Prina M. World Alzheimer report 2015. The global impact of dementia: an analysis of prevalence, incidence, cost and trends: Alzheimer's disease international; 2015.
39. Höckel M, Vaupel P, editors. Biological consequences of tumor hypoxia. Seminars in oncology; 2001: Elsevier.
40. Family L, Xu L, Xu H, Cannavale K, Sattayapiwat O, Page JH, Bohac C, Chao CJSCiC. The effect of chemotherapy-induced anemia on dose reduction and dose delay2016;24:4263-71.
41. Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer and Metastasis Reviews. 2007;26:225-39.
42. Macciò A, Madeddu C. Inflammation and ovarian cancer. Cytokine. 2012;58(2):133-47.
43. Sharma A, Jasrotia S, Kumar AJN-SsAoP. Effects of Chemotherapy on the Immune System: Implications for Cancer Treatment and Patient Outcomes2023:1-16.
44. Betts KA, Gao S, Ray S, Schoenfeld AJJFO. Real-world safety of first-line immuno-oncology combination therapies for advanced non-small-cell lung cancer2024(0).
45. Delano MJ, Moldawer LL. The origins of cachexia in acute and chronic inflammatory diseases. Nutrition in clinical practice. 2006;21(1):68-81.
46. Wang J, Li L, Xu ZPJSM. Enhancing Cancer Chemo‐Immunotherapy: Innovative Approaches for Overcoming Immunosuppression by Functional Nanomaterials2023:2301005.
47. Elena M-B, Jean-Hugues G, Belen P-OA, Christophe LJBR. Beyond current treatment of Fanconi Anemia: What do advances in cell and gene-based approaches offer?2023:101094.
48. Ladányi A, Somlai Bt, Gilde K, Fejös Z, Gaudi I, Tímár Jz. T-cell activation marker expression on tumor-infiltrating lymphocytes as prognostic factor in cutaneous malignant melanoma. Clinical Cancer Research. 2004;10(2):521-30.
49. Macciò A, Lai P, Santona MC, Pagliara L, Melis GB, Mantovani G. High serum levels of soluble IL-2 receptor, cytokines, and C reactive protein correlate with impairment of T cell response in patients with advanced epithelial ovarian cancer. Gynecologic oncology. 1998;69(3):248-52.
50. Maccio A, Madeddu C, Massa D, Mudu MC, Lusso MR, Gramignano G, Serpe R, Melis GB, Mantovani G. Hemoglobin levels correlate with interleukin-6 levels in patients with advanced untreated epithelial ovarian cancer: role of inflammation in cancer-related anemia. Blood. 2005;106(1):362-7.
51. Macciò A, Madeddu C, Massa D, Astara G, Farci D, Melis GB, Mantovani G. Interleukin‐6 and leptin as markers of energy metabolicchanges in advanced ovarian cancer patients. Journal of Cellular and Molecular Medicine. 2009;13(9b):3951-9.
52. Spivak JL. The anaemia of cancer: death by a thousand cuts. Nature Reviews Cancer. 2005;5(7):543-55.
53. Faquin WC, Schneider TJ, Goldberg MA. Effect of inflammatory cytokines on hypoxia-induced erythropoietin production1992.
54. Aboderin FI, Oduola T, Davison GM, Oguntibeju OOJB. A Review of the Relationship between the Immune Response, Inflammation, Oxidative Stress, and the Pathogenesis of Sickle Cell Anaemia2023;11(9):2413.
55. Yuan T, Jia Q, Zhu B, Chen D, Long HJCC, Signaling. Synergistic immunotherapy targeting cancer-associated anemia: prospects of a combination strategy2023;21(1):117.
56. Saini A, Nasser A-S, Stewart CE. Waste management—cytokines, growth factors and cachexia. Cytokine & growth factor reviews. 2006;17(6):475-86.
57. Burke SJ, Stadler K, Lu D, Gleason E, Han A, Donohoe DR, Rogers RC, Hermann GE, Karlstad MD, Collier JJ. IL-1β reciprocally regulates chemokine and insulin secretion in pancreatic β-cells via NF-κB. American journal of physiology-endocrinology and metabolism. 2015;309(8):E715-E26.
58. Al-Samkari H, Kessler CM, Auerbach MJh. Recognition of thrombotic risk of thrombocytosis in iron deficiency2021;106(3):661.
59. Oburoglu L, Romano M, Taylor N, Kinet S. Metabolic regulation of hematopoietic stem cell commitment and erythroid differentiation. Current Opinion in Hematology. 2016;23(3):198-205.
60. Koppenol WH, Bounds PL. The Warburg effect and metabolic efficiency: re-crunching the numbers. Science. 2009;324(5930):1029-33.
61. Montel-Hagen A, Sitbon M, Taylor N. Erythroid glucose transporters. Current opinion in hematology. 2009;16(3):165-72.
62. Oburoglu L, Tardito S, Fritz V, De Barros SC, Merida P, Craveiro M, Mamede J, Cretenet G, Mongellaz C, An X. Glucose and glutamine metabolism regulate human hematopoietic stem cell lineage specification. Cell stem cell. 2014;15(2):169-84.
63. Christ E, Cummings M, Westwood N, Sawyer B, Pearson T, Sonksen P, Russell-Jones D. The importance of growth hormone in the regulation of erythropoiesis, red cell mass, and plasma volume in adults with growth hormone deficiency. The Journal of Clinical Endocrinology & Metabolism. 1997;82(9):2985-90.
64. Jameus A, Kennedy AE, Thome CJD-R. Hematological changes following low dose radiation therapy and comparison to current standard of care cancer treatments2021;19(4):15593258211056196.
65. Iglesias P, Diez JJ, Fernandez-Reyes MJ, Aguilera A, Burgués S, Martinez-Ara J, Miguel JL, Gómez-Pan A, Selgas R. Recombinant human growth hormone therapy in malnourished dialysis patients: a randomized controlled study. American journal of kidney diseases. 1998;32(3):454-63.
66. Buck I, Morceau F, Grigorakaki C, Dicato M, Diederich M. Linking anemia to inflammation and cancer: the crucial role of TNFα. Biochemical pharmacology. 2009;77(10):1572-9.
67. Patel HJ, Patel BM. TNF-α and cancer cachexia: Molecular insights and clinical implications. Life sciences. 2017;170:56-63.
68. Nagasawa E, Abe Y, Nishimura J, Yanase T, Nawata H, Muta K. Pivotal role of peroxisome proliferator–activated receptor γ (PPARγ) in regulation of erythroid progenitor cell proliferation and differentiation. Experimental hematology. 2005;33(8):857-64.
69. McCranor BJ, Kim MJ, Cruz NM, Xue Q-L, Berger AE, Walston JD, Civin CI, Roy CN. Interleukin-6 directly impairs the erythroid development of human TF-1 erythroleukemic cells. Blood Cells, Molecules, and Diseases. 2014;52(2-3):126-33.
70. Strassmann G, Fong M, Kenney J, Jacob C. Evidence for the involvement of interleukin 6 in experimental cancer cachexia. The Journal of clinical investigation. 1992;89(5):1681-4.
71. Turnbull AV, Lee S, Rivier C. Mechanisms of Hypothalamic‐Pituitary‐Adrenal Axis Stimulation by Immune Signals in the Adult Rat a. Annals of the New York Academy of Sciences. 1998;840(1):434-43.
72. SANDLER S, BENDTZEN K, Eizirik DL, WELSH M. Interleukin-6 affects insulin secretion and glucose metabolism of rat pancreatic islets in vitro. Endocrinology. 1990;126(2):1288-94.
73. Madeddu C, Mantovani G, Gramignano G, Astara G, Macciò A. Muscle wasting as main evidence of energy impairment in cancer cachexia: future therapeutic approaches. Future Oncology. 2015;11(19):2697-710.
74. Epstein RS, Basu Roy UK, Aapro M, Salimi T, Moran D, Krenitsky J, Leone-Perkins ML, Girman C, Schlusser C, Crawford JJPp, adherence. Cancer patients’ perspectives and experiences of chemotherapy-induced myelosuppression and its impact on daily life2021:453-65.
75. Lazzari G, Silvano GJO, therapy. From anemia to erythropoietin resistance in head and neck squamous cell carcinoma treatment: a carousel driven by hypoxia2020:841-51.
76. Chung J, Bauer DE, Ghamari A, Nizzi CP, Deck KM, Kingsley PD, Yien YY, Huston NC, Chen C, Schultz IJ. The mTORC1/4E-BP pathway coordinates hemoglobin production with L-leucine availability. Science signaling. 2015;8(372):ra34-ra.
77. Doulatov S, Notta F, Laurenti E, Dick JE. Hematopoiesis: a human perspective. Cell stem cell. 2012;10(2):120-36.
78. Paulson RF, Hariharan S, Little JAJEh. Stress erythropoiesis: definitions and models for its study2020;89:43-54. e2.
79. Benedik PS, Hamlin SK. The physiologic role of erythrocytes in oxygen delivery and implications for blood storage. Critical Care Nursing Clinics. 2014;26(3):325-35.
80. Jewell UR, Kvietikova I, Scheid A, Bauer C, Wenger RH, Gassmann M. Induction of HIF–1α in response to hypoxia is instantaneous. The FASEB Journal. 2001;15(7):1312-4.
81. Semenza GL. Surviving ischemia: adaptive responses mediated by hypoxia-inducible factor 1. The Journal of clinical investigation. 2000;106(7):809-12.
82. Zheng H, Jiang L, Tsuduki T, Conrad M, Toyokuni SJRb. Embryonal erythropoiesis and aging exploit ferroptosis2021;48:102175.
83. Tsiftsoglou ASJC. Erythropoietin (EPO) as a key regulator of erythropoiesis, bone remodeling and endothelial transdifferentiation of multipotent mesenchymal stem cells (MSCs): implications in regenerative medicine2021;10(8):2140.
84. Bennett G, Kay M. Homeostatic removal of senescent murine erythrocytes by splenic macrophages. Experimental hematology. 1981;9(3):297-307.
85. Palis J. Primitive and definitive erythropoiesis in mammals. Frontiers in physiology. 2014;5:3.
86. Ludwig H, Van Belle S, Barrett-Lee P, Birgegård G, Bokemeyer C, Gascón P, Kosmidis P, Krzakowski M, Nortier J, Olmi P. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. European journal of cancer. 2004;40(15):2293-306.
87. Men JG, Tang J, Ding J, Chen X, Su J-M, Liu J-Y. Prevalence and characteristics of anemia in patients with solid cancers at diagnosis in southwest China. Asian Pacific Journal of Cancer Prevention. 2011;12:2825-8.
88. Hassan B, Yusoff Z, Hassali MA, Othman SB. Association and correlation of different chemotherapeutic regimens and doses with onset and severity of anemia among solid cancer patients. Asian Pac J Cancer Prev. 2011;12(10):2753-8.
89. Hassan BAR, Yusoff ZBM. Treatment patterns and outcomes in management of solid cancer patients suffering from anemia in Penang hospital. Asian Pac J Cancer Prev. 2011;12(6):1573-6.
90. Auerbach M, Muñoz M. Intravenous iron for treating cancer-induced anemia: meeting an unmet need? Chin Clin Oncol. 2012;1:21-3.
91. Auerbach M, Ballard H, Trout JR, McIlwain M, Ackerman A, Bahrain H, Balan S, Barker L, Rana J. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. Journal of Clinical Oncology. 2004;22(7):1301-7.
92. Avni T, Bieber A, Grossman A, Green H, Leibovici L, Gafter-Gvili A, editors. The safety of intravenous iron preparations: systematic review and meta-analysis. Mayo clinic proceedings; 2015: Elsevier.
93. Baek JH, D’Agnillo F, Vallelian F, Pereira CP, Williams MC, Jia Y, Schaer DJ, Buehler PW. Hemoglobin-driven pathophysiology is an in vivo consequence of the red blood cell storage lesion that can be attenuated in guinea pigs by haptoglobin therapy. The Journal of clinical investigation. 2012;122(4):1444-58.
94. Grogan M, Thomas GM, Melamed I, Wong FL, Pearcey RG, Joseph PK, Portelance L, Crook J, Jones KD. The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer. 1999;86(8):1528-36.
95. Newhall D, Oliver R, Lugthart SJNJM. Anaemia: A disease or symptom2020;78(3):104-10.
96. Dugan C, MacLean B, Cabolis K, Abeysiri S, Khong A, Sajic M, Richards T, Anaesthesia WsHrCJ. The misogyny of iron deficiency2021;76:56-62.
97. Bhadra P, Deb AJIJoNS. A review on nutritional anemia2020;10(59):18466-74.
98. Mattiello V, Schmugge M, Hengartner H, von der Weid N, Renella R, pediatrics SPHWGJEjo. Diagnosis and management of iron deficiency in children with or without anemia: consensus recommendations of the SPOG Pediatric Hematology Working Group2020;179:527-45.
99. Anand S, Burkenroad A, Glaspy JJCAHO. Workup of anemia in cancer2020;18(10):640-6.
100. Dainiak N, Kulkarni V, Howard D, Kalmanti M, Dewey MC, Hoffman R. Mechanisms of abnormal erythropoiesis in malignancy. Cancer. 1983;51(6):1101-6.
101. Doll DC, Weiss RB. Chemotherapeutic agents and the erythron. Cancer Treatment Reviews. 1983;10(3):185-200.
102. Miller CB, Jones RJ, Piantadosi S, Abeloff MD, Spivak JL. Decreased erythropoietin response in patients with the anemia of cancer. New England Journal of Medicine. 1990;322(24):1689-92.
103. Bokemeyer C, Oechsle K, Hartmann JT. Anaemia in cancer patients: pathophysiology, incidence and treatment. European journal of clinical investigation. 2005;35:26-31.
104. Mesa R, Gerds A, Vannucchi A, Al-Ali HK, Lavie D, Kuykendall A, Grosicki S, Iurlo A, Goh YT, Lazaroiu MJJoON, Survivorship. MOMENTUM: Phase 3 randomized study of momelotinib (MMB) versus danazol (DAN) in symptomatic and anemic myelofibrosis (MF) patients previously treated with a JAK inhibitor2022;13(11).
105. Mhaskar R, Wao H, Miladinovic B, Kumar A, Djulbegovic B. The role of iron in the management of chemotherapy‐induced anemia in cancer patients receiving erythropoiesis‐stimulating agents. Cochrane Database of Systematic Reviews. 2016(2).
106. Fishbane S, Kowalski EA, editors. The comparative safety of intravenous iron dextran, iron saccharate, and sodium ferric gluconate. Seminars in dialysis; 2000: Wiley Online Library.
107. Baribeault D, Auerbach M. Iron replacement therapy in cancer-related anemia. American Journal of Health-System Pharmacy. 2011;68(10_Supplement_1):S4-S14.
108. Rodgers III G, Gilreath J, Achebe M, Alwan L, Arcasoy M, Ali Beth S. NCCN. Cancer-and Chemotherapy-Induced Anemia, Version 2.2017. 2017.
109. Birgegård G, Henry D, Glaspy J, Chopra R, Thomsen LL, Auerbach M. A randomized noninferiority trial of intravenous iron isomaltoside versus oral iron sulfate in patients with nonmyeloid malignancies and anemia receiving chemotherapy: the PROFOUND trial. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2016;36(4):402-14.
110. Steensma DP, Sloan JA, Dakhil SR, Dalton R, Kahanic SP, Prager DJ, Stella PJ, Rowland Jr KM, Novotny PJ, Loprinzi CL. Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia. Journal of Clinical Oncology. 2011;29(1):97.
111. Gabrilove JL, Cleeland CS, Livingston RB, Sarokhan B, Winer E, Einhorn LH. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. Journal of Clinical Oncology. 2001;19(11):2875-82.
112. Goodnough LT, Nemeth E, Ganz T. Detection, evaluation, and management of iron-restricted erythropoiesis. Blood, The Journal of the American Society of Hematology. 2010;116(23):4754-61.
113. Ludwig H, Aapro M, Bokemeyer C, Glaspy J, Hedenus M, Littlewood TJ, Österborg A, Rzychon B, Mitchell D, Beguin Y. A European patient record study on diagnosis and treatment of chemotherapy-induced anaemia. Supportive Care in Cancer. 2014;22:2197-206.
114. Naoum FA. Iron deficiency in cancer patients. Revista brasileira de hematologia e hemoterapia. 2016;38:325-30.
115. Aapro M, Beguin Y, Bokemeyer C, Dicato M, Gascón P, Glaspy J, Hofmann A, Link H, Littlewood T, Ludwig H. Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines. Annals of Oncology. 2018;29:iv96-iv110.
116. Mustafai FA, Balouch A, Abdullah, Jalbani N, Bhanger MI, Jagirani MS, Kumar A, Tunio A. Microwave-assisted synthesis of imprinted polymer for selective removal of arsenic from drinking water by applying Taguchi statistical method. European Polymer Journal. 2018;109:133-42. doi: https://doi.org/10.1016/j.eurpolymj.2018.09.041.
117. Weigl A, Köhler N, Monsef I, Bohlius J, Kuhr K, Becker I, Skoetz N. Intravenous iron versus oral iron versus no iron with or without erythropoiesis‐stimulating agents (ESA) for cancer patients with anaemia: A systematic review and network meta‐analysis. The Cochrane Database of Systematic Reviews. 2017;2017(4).
118. Birgegård G, Aapro MS, Bokemeyer C, Dicato M, Drings P, Hornedo J, Krzakowski M, Ludwig H, Pecorelli S, Schmoll H-J. Cancer-related anemia: pathogenesis, prevalence and treatment. Oncology. 2005;68(Suppl. 1):3-11.
119. Henry D, Brooks Jr B, Case Jr D, Fishkin E, Jacobson R, Keller A, Kugler J, Moore J, Silver R, Storniolo A. Recombinant human erythropoietin therapy for anemic cancer patients receiving cisplatin chemotherapy. The cancer journal from Scientific American. 1995;1(4):252-60.
120. Vansteenkiste J, Glaspy J, Henry D, Ludwig H, Pirker R, Tomita D, Collins H, Crawford J. Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: study-level and patient-level meta-analyses. Lung Cancer. 2012;76(3):478-85.
121. Thorp ML, Johnson ES, Yang X, Petrik AF, Platt R, Smith DH. Effect of anaemia on mortality, cardiovascular hospitalizations and end‐stage renal disease among patients with chronic kidney disease. Nephrology. 2009;14(2):240-6.
122. Bohlius J, Wilson J, Seidenfeld J, Piper M, Schwarzer G, Sandercock J, Trelle S, Weingart O, Bayliss S, Djulbegovic B. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. Journal of the National Cancer Institute. 2006;98(10):708-14.
123. NELSON AH, FLEISHER LA, ROSENBAUM SH. Relationship between postoperative anemia and cardiac morbidity in high-risk vascular patients in the intensive care unit. Critical care medicine. 1993;21(6):860-6.
124. Watkins T, Surowiecka MK, McCullough J. Transfusion indications for patients with cancer. Cancer Control. 2015;22(1):38-46.
125. Eder AF, Chambers LA. Noninfectious complications of blood transfusion. Archives of pathology & laboratory medicine. 2007;131(5):708-18.
126. Koeller JM. Clinical guidelines for the treatment of cancer‐related anemia. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 1998;18(1):156-69.
127. Schrijvers D. Management of anemia in cancer patients: transfusions. The oncologist. 2011;16(S3):12-8.
128. Bryer E, Henry D. Chemotherapy-induced anemia: etiology, pathophysiology, and implications for contemporary practice. International Journal of Clinical Transfusion Medicine. 2018:21-31.
129. Spivak JL, Gascón P, Ludwig H. Anemia management in oncology and hematology. The oncologist. 2009;14(S1):43-56.
130. Javarappa KK, Tsallos D, Heckman CA. A multiplexed screening assay to evaluate chemotherapy-induced myelosuppression using healthy peripheral blood and bone marrow. SLAS DISCOVERY: Advancing Life Sciences R&D. 2018;23(7):687-96.
131. Taylor SJ, Duyvestyn JM, Dagger SA, Dishington EJ, Rinaldi CA, Dovey OM, Vassiliou GS, Grove CS, Langdon WY. Preventing chemotherapy-induced myelosuppression by repurposing the FLT3 inhibitor quizartinib. Science translational medicine. 2017;9(402):eaam8060.
132. Masoud GN, Li W. HIF-1α pathway: role, regulation and intervention for cancer therapy. Acta Pharmaceutica Sinica B. 2015;5(5):378-89.
133. Miller RL, Sandoval PC, Pisitkun T, Knepper MA, Hoffert JD. Vasopressin inhibits apoptosis in renal collecting duct cells. American journal of physiology-renal physiology. 2013;304(2):F177-F88.
134. Carrancio S, Markovics J, Wong P, Leisten J, Castiglioni P, Groza MC, Raymon HK, Heise C, Daniel T, Chopra R. An activin receptor II A ligand trap promotes erythropoiesis resulting in a rapid induction of red blood cells and haemoglobin. British Journal of Haematology. 2014;165(6):870-82.
135. Madeddu C, Gramignano G, Astara G, Demontis R, Sanna E, Atzeni V, Macciò A. Pathogenesis and treatment options of cancer related anemia: perspective for a targeted mechanism-based approach. Frontiers in physiology. 2018;9:1294.
136. Gilreath JA, Rodgers GM. How I treat cancer-associated anemia. Blood, The Journal of the American Society of Hematology. 2020;136(7):801-13.
137. Goodnough LT, Brecher ME, Kanter MH, AuBuchon JP. Transfusion medicine—blood transfusion. New England journal of medicine. 1999;340(6):438-47.